RYTM Q3 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+54.3% YoY

Gross Profit

$46M89.3% margin

Operating Income

-$53M-102.6% margin

Net Income

-$53M-103.1% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$507M

Total Liabilities

$358M

Stockholders' Equity

$149M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$33M	+54.3%
Gross Profit	$46M	$29M	+55.7%
Operating Income	-$53M	-$44M	-20.0%
Net Income	-$53M	-$44M	-21.2%

Revenue Segments

Product

$51M100%

Geographic Segments

Non-US

$13M100%